OnKure Therapeutics, Inc., was incorporated in Delaware on September 22, 2014. OnKure is a clinical-stage biopharmaceutical company focused on the discovery and development of best-in-class precision medicines for bio-validation drivers of cancers that are underserved by available therapies. Using a structure-based drug design platform, OnKure is building a strong pipeline of oncology agnostic drug candidates designed to achieve optimal efficacy and tolerability. OnKure is developing OKI-219, a selective PI3KαH1047R inhibitor, as its lead project. OnKure aims to be a leader in targeting carcinogenic PI3Kα and has several best-in-class targeting projects aimed at achieving this key oncogene.